Medicare’s National Coverage Determination for Aducanumab — A One-Off or a Pragmatic Path Forward?

Medicare’s National Coverage Determination for Aducanumab — A One-Off or a Pragmatic Path Forward?

As it did with aducanumab, CMS could use the coverage with evidence development program to address residual uncertainty regarding benefits and harms for an increasing number of FDA-regulated products.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2022-10, Vol.387 (17), p.1539-1541
Hauptverfasser: Dhruva, Sanket S., Ramachandran, Reshma, Ross, Joseph S.
Format: Artikel
Sprache:eng
Schlagworte:
Aging
Aging General
Alzheimer Disease
Alzheimer's disease
and the FDA
Beneficiaries
Clinical outcomes
Dementia
Devices
Drugs
Enrollments
FDA approval
Geriatrics
Health Policy
Medical equipment
Medicare
Medicare and Medicaid
Monoclonal antibodies
Neurology
Neurosurgery
Older people
Patients
Prescription drugs
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:As it did with aducanumab, CMS could use the coverage with evidence development program to address residual uncertainty regarding benefits and harms for an increasing number of FDA-regulated products.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMp2210198